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Am J Physiol Endocrinol Metab 298: E1072–E1077, 2010. First published
March 2, 2010; doi:10.1152/ajpendo.00728.2009.—The proinflammatory
and proatherogenic mediator, soluble CD40 ligand (CD40L), is
increased in the metabolic syndrome (MS) and released from
platelets. We hypothesized that adiponectin modulates platelet
function, and we sought to evaluate the association of adiponectin and
sCD40L levels with platelet aggregation in MS and the effects of
adiponectin on platelet aggregation and activation. Platelet aggregation
and circulating adiponectin, sCD40L and P-selectin were determined in
30 controls and 30 patients with MS. Also, in vitro studies were per-
formed in platelet-rich plasma from nine healthy volunteers. Adiponectin
receptors were demonstrated by Western blotting and flow cytometry.
ADP and epinephrine platelet aggregation was measured after preincu-
bation with adiponectin. sCD40L and P-selectin secretion was measured
in the supernatants by ELISA. Patients with MS had higher sCD40L and
P-selectin than controls (5.96  0.50 vs. 4.28  0.41 ng/ml, P  0.05,
and 151 8 vs. 122 9 ng/ml, P 0.05). By contrast, adiponectin was
lower in patients with MS than in controls (5.25  0.30 vs. 7.35  0.34
g/ml, P  0.001). Higher platelet aggregation was found in MS.
Adiponectin inversely correlated with P-selectin (R  0.35, P 
0.009), sCD40L (r  0.24, P  0.05) and epinephrine and collagen
induced aggregation (r  0.80, P  0.005; r  0.70, P  0.011).
Platelets express the receptors for adiponectin. Platelet aggregatory re-
sponse to epinephrine and ADP significantly decreased following prein-
cubation with adiponectin (96  4 vs. 23  3%, P  0.001, and 102 
9 vs. 85  9%, P  0.004). Adiponectin prevented platelet sCD40L
release (1.63  0.15 vs. 2.04  0.20 ng/ml, P  0.001). Enhanced
platelet aggregation and activation markers are found in MS associated
with low adiponectin concentrations. Novel evidence is provided dem-
onstrating that adiponectin has antithrombotic properties, since it inhibits
platelet aggregation and platelet activation.
soluble CD40 ligand; platelets; platelet activation; P-selectin
THE METABOLIC MYNDROME (MS) consists of the convergence of a
variety of risk factors in the same individual and is characterized
by a general proinflammatory and prothrombotic state that inter-
acts synergistically, causing or accelerating the progression of
atherosclerosis. There are different definitions to describe this
syndrome. Currently, the more accepted definitions are those of
the National Cholesterol Education Program - Third Adult Treat-
ment Panel (NCEP ATP III) and the World Health Organiza-
tion (WHO). In both, obesity, insulin resistance, dyslipidemia,
and hypertension are considered to underlie the metabolic
syndrome. Prothrombosis is not yet included in any definition
of MS, but the International Diabetes Federation (IDF) con-
sensus group identifies a prothrombotic state related to MS and
advises investigating the predictive power of these extra crite-
ria for cardiovascular risk or diabetes. In fact, several investi-
gations demonstrate the association between a prothrombotic
state and diabetes (23), obesity (20), and hypertension (17).
Furthermore, recent studies demonstrate that obesity increases
platelet reactivity (18). Indeed, there are studies that show that
patients with MS have higher platelet count (9), increased
platelet reactivity and turnover, and lower antiplatelet response
to aspirin than controls (24, 25).
CD40 ligand (CD40L) is a proinflammatory mediator ex-
pressed with its receptor CD40 in a wide variety of cells. There
is in vitro and in vivo evidence of their participation in
atherothrombosis. In addition to the cellular form of CD40L,
there is a soluble form (sCD40L) secreted by activated plate-
lets, which circulates in plasma. Our group has previously
described that patients with MS have higher platelet derived
soluble CD40L than controls (15).
Adipose tissue, in excess in patients with MS, secretes,
among other cytokines, adiponectin. Reduced adiponectin se-
rum levels correlate with obesity (11), insulin resistance (7),
and type 2 diabetes (3). In addition to its metabolic actions,
adiponectin has anti-inflammatory and antiatherogenic effects
through its receptors (AdipoR1 and AdipoR2) expressed on
monocytes, smooth muscle cells, and endothelial cells. Fur-
thermore, there are investigations that confer an antithrombotic
role on adiponectin (10) and associate platelet activation with
low serum adiponectin (4). The aims of the present work were
1) to compare platelet aggregation and sCD40L levels in
patients with MS and evaluate its association with adiponectin
concentrations and 2) to study the in vitro effects of adiponec-
tin on platelet aggregation and sCD40L release.
METHODS
Reagents. Recombinant human adiponectin was purchased from
Preprotech. Endotoxin level was less than 0.1 ng/g. Epinephrine,
L-adenosine 52-diphosphate, and collagen were purchased from
Arkray. The anti-adiponectin antibody was purchased from R&D
Systems.
Study population. The study was performed in 30 healthy individ-
uals (controls) and 30 patients with MS attending the Internal Medi-
cine Department of the Clínica Universidad de Navarra for a general
check-up. All participants underwent a complete medical examina-
tion. MS was diagnosed according to the National Cholesterol Edu-
cation Program - Adult Treatment Panel III guidelines, with modifi-
cation of waist criterion into body mass index (BMI  30 kg/m2).
Exclusion criteria were the presence of impaired renal or liver func-
tion, arteritis, connective tissue diseases, chronic inflammatory dis-
eases, coronary artery disease, or stroke. None of the patients had
taken aspirin, platelet glycoprotein IIb/IIIa inhibitors, or thienopyri-
dines in the previous 6 mo.
Anthropometric measurements, including weight and height, were
obtained using standardized techniques. BMI was calculated using the
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formula weight (kg)/height2(m). Blood pressure was measured on the
right arm with a mercury sphygmomanometer with the subjects in a
seated position and after a 5-min rest. The average of two measure-
ments, at the beginning and end of the visit, was considered.
In one subgroup of the population, platelet aggregation was mea-
sured (8 controls and 7 patients with MS). In addition, for the platelet
in vitro studies, citrated blood was obtained from nine healthy vol-
unteers who had not taken any medication known to affect platelet
function in the previous month.
The local Committee on Human Research approved the study,
performed in accordance with the Declaration of Helsinki, and all
participants provided written informed consent.
Biochemical analyses. Serum and plasma of patients and controls
were collected into Vacutainer tubes. Fasting serum glucose, choles-
terol, triglycerides, and high-density lipoprotein cholesterol were
measured by standard laboratory techniques.
Serum adiponectin and P-selectin were measured by ELISA (R&D
System, Minneapolis, MN) according to the manufacturer’s instruc-
tions. The detection limits were 0.003 and 0.010 ng/ml, respectively.
sCD40L levels in serum and in platelet supernatants were determined
by ELISA (BenderMedSystems, Vienna, Austria). The within-assay
coefficient of variation for all assays was 10%.
Human platelet aggregation studies. Platelet-rich plasma (PRP)
was prepared by centrifugation of whole citrated blood at 120 g for 10
min at 20°C. Supernatants were drawn into another tube, and the
remaining blood was centrifuged at 1,200 g for 15 min to obtain
platelet-poor plasma (PPP). Platelet count was performed in the
automatic hematology analyzer ABX Pentra 60 (Horiba ABX Diag-
nostics, France). The PRP was diluted with the PPP corresponding to
each patient to obtain a final concentration of 400  106 platelets/ml.
Platelet aggregation was measured in the subgroup of 15 patients
by activating platelets through the addition of epinephrine (3.34
g/ml), L-adenosine 52-diphosphate (ADP, 1 g/ml), or collagen (5
g/ml) for 5 min at 37°C under constant stirring (10,000 rpm) in an
automated platelet aggregation recorder (Aggrecorder II; DIC Kyoto
Daiichi Chemical, kyoto, Japan). This aggregometer measures the
variation in absorbance caused by platelet aggregation after the
addition of an inducer (ADP, collagen, epinephrine, etc.) to the PRP.
The data used for diagnosis are the aggregation pattern of the maxi-
mum aggregation ratio setting PPP at 0%.
Dose-response curves to adiponectin (0–40 g/ml) were per-
formed in two healthy volunteers to select an adequate concentration
to study the effect of adiponectin on platelet aggregation and sCD40L
release. PRP from healthy volunteers (n  9) was preincubated with
or without adiponectin (final concentration 25 g/ml; Peprotech) for
40 min at 37°C before the addition of the platelet aggregation inducer.
The specificity of the effects was evaluated preincubating adiponectin
with an anti-adiponectin antibody (25 g/ml) for 30 min at 37°C.
Then, the blocked adiponectin was added, and platelets were stimu-
lated with ADP or epinephrine.
Effect of adiponectin on platelet sCD40L secretion. To investigate
the effects of adiponectin on platelet sCD40L secretion, PRP from
each healthy volunteer (n  9) was pretreated with or without
adiponectin (25 g/ml) for 40 min at 37°C. Then, maximal sCD40L
release was induced through the incubation with L-adenosine 52-
diphosphate (ADP, 5.5 g/ml) for 30 min at 37°C. Aliquots were
centrifuged at 3,500 rpm for 7 min. Supernatants were collected, and
sCD40L was measured by ELISA. Pellets were resuspended in plate-
let lysis buffer [20 mmol/l Tris (pH 7.4), 150 mmol/l NaCl, 1% Triton
X-100, and 1 mmol/l EDTA].
Western blotting. Platelet lysates were used to explore the expres-
sion of the receptors of adiponectin, AdipoR1 and AdipoR2, by
Western blotting. Protein concentration in platelet lysates was as-
sessed by the Bradford method (Bio-Rad, Hercules, CA). Thirty
micrograms of protein was fractionated on 12% polyacrylamide gels
and transferred into nitrocellulose membranes. Membranes were
blocked (10% nonfat dry milk in 0.05% Tween 20-TBS) and incu-
bated with a goat monoclonal antihuman AdipoR1 (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA) or AdipoR2 (1:200; Santa Cruz
Biotechnology). Bound antibody was detected by peroxidase-conju-
gated secondary antibody (donkey anti-goat 1:10,000, Santa Cruz
Biotechnology) and visualized using the ECL-Plus chemilumines-
cence detection system (Amersham Biosciences, Piscataway, NJ). We
included protein extracts from human heart as a negative control.
Flow cytometry. Human platelets from three different healthy
donors were analyzed for surface expression of AdipoR1 and AdipoR2
by staining with fluorescein isothiocyanate (FITC)-coupled antibod-
ies. FITC antibodies were added to the PRP at a final concentration of
5 g/ml and incubated at room temperature for 30 min. Cells were
analysed in a Bekcman Coulter Epics XL flow cytometer. Isotope-
matched IgG was employed as a control. The results are expressed as
the mean intensity of fluorescence (MIF) of adiponectin receptors.
Statistical analysis. Statistical analysis was performed using the
Statistical Package for the Social Sciences (SPSS) version 15.0.
Normal distribution of samples was assessed by the Shapiro-Wilks test.
Differences between study groups were evaluated by the Student’s t-test
for normally or Mann-Whitney U-test for nonnormally distributed vari-
ables and 2 statistic for categorical variables. To investigate differences
between experimental conditions, paired Student’s t-test, Wilcoxon
signed rank test, and Kruskal-Wallis test were used. Pearson and Spear-
man’s correlation test assessed univariate correlations. Multivariable
linear regression analysis was used to determine whether the association
between adiponectin and sCD40L and P-selectin was independent of
other confounding factors. For all statistical testing, two-sided probability
values were reported, and statistical significance was established at P 
0.05. Data are expressed as means  SE.
RESULTS
In vivo studies. The general characteristics of the study
population are presented in Table 1. As expected, patients with
MS exhibited significantly (P  0.05) higher BMI, systolic
blood pressure (SBP), diastolic blood pressure (DBP), glucose,
cholesterol, and triglycerides levels and lower HDL-choles-
terol levels than controls.
Patients with MS had significantly higher serum levels of the
markers of platelet activation sCD40L and P-selectin than controls
(5.96  0.50 vs. 4.28  0.41 ng/ml, P  0.05, and 151  8 vs.
122  9 ng/ml, P  0.05). By contrast, adiponectin levels were
Table 1. Demographic and clinical characteristics of the
study population
Variables
No Metabolic
Syndrome
Metabolic
Syndrome P Value
Age, yr 44  2 60  2 0.001
Male, % 50 73 0.033
BMI, kg/m2 27  2 35  1 0.011
Systolic arterial pressure, mmHg 127  6 150  4 0.012
Diastolic arterial pressure, mmHg 72  5 89  2 0.001
Statins treatment, % 0 15 0.001
Antihypertensive treatment, % 0 25 0.001
Glucose, mg/dl 94  2 116  4 0.001
Total cholesterol, mg/dl 192  7 217  8 0.033
Triglycerides, mg/dl 76  6 143  8 0.001
HDL-cholesterol, mg/dl 60  3 47  2 0.001
LDL-cholesterol, mg/dl 121  7 139  6 NS
Adiponectin, g/ml 7.35  0.3 5.25  0.3 0.001
sCD40L, ng/ml 4.28  0.4 5.96  0.5 0.013
P-selectin, ng/ml 122  9 151  8 0.025
Values are means  SE; n  30. sCD40L, soluble CD40 ligand; NS,
nonsignificant.
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significantly lower in patients with MS than in controls (5.25 
0.30 vs. 7.35  0.34 g/ml, P  0.001) (Fig. 1).
Platelet aggregation induced by ADP or collagen was signifi-
cantly higher in patients with MS than in the control population
(96 4 vs. 86 2%, P 0.038, and 99 3 vs. 91 3%, P
0.041). Although epinephrine-induced aggregation tended to be
higher in patients with MS (98 3 vs. 89 3%, P 0.08), it did
not reach statistical significance.
We next explored the association between circulating levels
of adiponectin and sCD40L with other biochemical and demo-
graphic parameters. sCD40L levels correlated with some fac-
tors of MS (triglycerides r  0.49, P  0.006, and HDL-
cholesterol r  0.53, P  0.023; Table 2). Similarly, adi-
ponectin inversely correlated with triglycerides (r  0.49, P
 0.001), BMI (r  0.33, P  0.050), and glucose (r 
0.46, P  0.001) and directly with HDL-cholesterol (r 
0.59, P  0.001). P-selectin and sCD40L concentrations cor-
related with platelet count (r  0.44, P  0.006, and r  0.35,
P  0.041, respectively). Interestingly, in the whole popula-
tion, levels of adiponectin inversely and significantly corre-
lated with the markers of platelet activation P-selectin (r 
0.35, P  0.009) and sCD40L (r  0.24, P  0.05) (Fig.
2). After adjustments for age and sex, adiponectin significantly
associated with P-selectin (  0.40, P 0.01) and sCD40L
(  0.31, P  0.05). Importantly, in the subgroup, adi-
ponectin significantly and inversely correlated with epineph-
rine- and collagen-induced aggregation (r  0.80, P 
0.005, and r  0.70, P  0.011, respectively) and nearly
reached significance with ADP-induced aggregation (r 
0.59, P  0.06).
Effect of adiponectin on platelet aggregation. To investigate
whether platelets could respond to adiponectin, we tested by
Western blotting whether platelets from healthy volunteers
expressed the receptors for adiponectin. Western blot analysis
revealed the presence of immunoreactive bands at the expected
molecular mass (AdipoR1, 42 kDa; AdipoR2, 35 kDa) in all
donors (Fig. 3). Nonactivated human platelets were analysed
by flow cytometry for the expression of adiponectin receptors
on the cell surface. An increase in MIF was found for both
AdipoR1 and AdipoR2 (152  20 and 539  22) compared
with the isotope control. AdipoR1 and AdipoR2 expression
was compared in platelets obtained from patients with and
without MS. No statistically significant differences were found
in AdipoR1 or AdipoR2 in patients with MS compared with
controls (1.52  0.43 vs. 1.34  0.12 arbitrary units or 2.29 
0.87 vs. 1.11  0.29 arbitrary units).
Once it was demonstrated that platelets express receptors for
adiponectin, we next studied the effects of adiponectin on platelet
aggregation by pretreating platelets with increasing concentrations
of adiponectin (range 0–40 g/ml). Adiponectin dose-depen-
Fig. 1. Serum levels of soluble CD40 ligand (sCD40L), adiponectin, and
P-selectin in healthy donors and patients with metabolic syndrome (MS).
P-selectin (A), sCD40L (B), and adiponectin (C) serum concentrations were
measured by ELISA in patients with and without MS (n  30 in both groups).
Histograms represent means  SE.
Fig. 2. Correlations of circulating adiponectin with P-selectin and sCD40L. Serum
P-selectin, sCD40L, and adiponectin were measured in patients with and without
MS (both n  30). Scatter plots show correlations of circulating adiponectin with
P-selectin (A) and sCD40L (B) in patients with and without MS.
Fig. 3. Platelets express the adipokine receptors AdipoR1 and AdipoR2.
Platelet protein extracts (30 g) from 5 healthy donors were separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blotting
analysis, showing a positive band at the expected molecular weight of AdipoR1
(A) and AdipoR2 (B). The last lane corresponds to a protein extract obtained from
human heart employed as a negative control.
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dently decreased epinephrine- and ADP-induced aggregation
(Fig. 4, A and B). The effects of adiponectin on collagen-induced
aggregation were not so clear, so in follow-up we decided to
employ epinephrine and ADP for the in vitro studies. The aggre-
gatory response to epinephrine significantly decreased in platelets
following preincubation with adiponectin (25 g/ml; 96  4 vs.
23 3%, P 0.001; Fig. 4C). Similarly, adiponectin (25 g/ml)
significantly decreased ADP-induced aggregation (102  9 vs.
85  9%, P  0.004; Fig. 4D).
To ensure that the observed effects were specific to adi-
ponectin, this adipocytokine was preincubated with an anti-
adiponectin antibody (100 ng/ml, 30 min, 37°C). Subse-
quently, the blocked adiponectin was added to the platelets
(n  3), and they were stimulated with epinephrine or ADP.
When adiponectin was preblocked with a specific antibody,
there was a reduction of the effect of adiponectin, as epineph-
rine-induced aggregation of control platelets was 89  1%,
incubated with adiponectin 18  1%, and incubated with
anti-adiponectin antibody 41  1%. ADP-induced aggregation
of control platelets was 88  1%, with adiponectin 20  1%,
and with the blocked adiponectin 57  1%. This is a reduction
of the effect mediated by adiponectin in epinephrine- and
ADP-induced platelet aggregation of 67 and 51%, respectively.
Effect of adiponectin on P-selectin and sCD40L release. We
next aimed to study platelet activation by measuring biomarkers
released from platelet 	-granules upon activation with different
agonists. ADP was employed as a potent inductor of sCD40L and
P-selectin release. sCD40L and P-selectin were quantified in
platelet supernatants following stimulation and centrifugation.
Interestingly, adiponectin significantly and dose-dependently de-
creased sCD40L release (Fig. 5A). Maximal effect was observed
at 25 g/ml. This concentration was selected in order to evaluate
the effect in all donors. ADP-induced P-selectin release was
significantly prevented by adiponectin (1.77 vs. 1.07 ng/ml). ADP
significantly increased sCD40L release (nonstimulated vs. stimu-
lated: 1.63 0.15 vs. 4.38 0.31 ng/ml, P 0.001; Fig. 5B) and
preincubation of platelets with adiponectin significantly prevented
sCD40L release (4.38 0.31 and 2.04 0.20 ng/ml, P 0.001;
Fig. 5B). Preincubation of adiponectin with an anti-adiponectin
antibody before its addition to the platelets resulted in a 55%
reduction in sCD40L platelet release. Adiponectin alone had no
effect on sCD40L release.
DISCUSION
The main findings of the current study are the following:
1) sCD40L, P-selectin, and platelet aggregation are increased in
Fig. 4. Adiponectin diminishes platelet aggre-
gation. Platelet-rich plasma (n  2) was incu-
bated with increasing concentrations of adi-
ponectin (0–40 g/ml). Light transmission ag-
gregometry was used to assess degree of
platelet aggregation in response to epinephrine
(A) and ADP (B). Epinephrine (C) and ADP
(D) aggregation was measured in healthy do-
nors (n  9) after incubation with adiponectin
(25 g/ml) for 40 min at 37°C. Data are ex-
pressed as means  SE.
Fig. 5. Adiponectin reduces platelet sCD40L release. Platelet-rich plasma was
incubated with increasing concentrations of adiponectin (0–40 g/ml). Following
incubation, sCD40L release was induced with ADP (5.5 g/ml, 30 min, 37°C).
Samples were centrifuged (3,500 rpm, 7 min) and sCD40L (A) was measured in
the supernatants by ELISA. Platelet-rich plasma from healthy volunteers was
treated with or without adiponectin (25g/ml, 40 min, 37°C), and sCD40L release
was measured in the supernatants (B). Histograms represent means  SE. *P 
0.05 vs. stimulation with ADP without adiponectin.
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MS and adiponectin inversely correlates with sCD40L, P-selectin,
and platelet aggregation; 2) platelets express the adiponectin
receptors AdipoR1 and AdipoR2; and 3) adiponectin inhibits
platelet aggregation and platelet P-selectin and sCD40L release.
Metabolic syndrome and prothrombosis. It is known that
patients with MS present a proinflammatory and prothrombotic
state. The individual risk factors obesity (2), diabetes (24), and
hypertension (29) and also MS (24) have been associated with
high platelet activity. The data from the present study show that
patients with MS exhibited higher platelet activity compared with
control subjects, which is in agreement with previous publications
(24). Also, the present study confirms previous reports describing
higher levels of the markers of platelet activation P-selectin and
sCD40L and lower levels of adiponectin in patients with MS than
in controls (12, 14, 15, 21, 22). Our group (15, 27) previously
demonstrated that platelets from patients with diabetes or MS
release higher amounts of sCD40L than platelets from controls,
which could account for the elevated sCD40L levels observed in
these patients. Glucose and advanced glycation end products have
been described as potential triggers (26), but other mediators can
be involved. Here, we identify adiponectin as a mediator of
obesity-related cardiovascular complications that also modulates
platelet sCD40L release. As platelets are the main source of
circulating sCD40L, it is tempting to speculate that, in conditions
where there is a decrease of adiponectin, such as obesity, diabetes,
or insulin resistance, the control of platelet activation and aggre-
gation will be diminished. The finding of low adiponectin levels
and high aggregation in patients with MS and the negative
correlation of adiponectin with sCD40L circulating levels sup-
ports this hypothesis.
Some studies have evaluated the association of platelet count
with MS with controversial results (9, 13, 28). We did not find
differences in platelet count between controls and patients with
MS, but sCD40L levels increased along with platelet count.
Effects of adiponectin on platelet aggregation. Adipose tis-
sue is an endodrine organ that releases bioactive molecules
known as adipokines. One of them, adiponectin, has been
described to present antiatherogenic and anti-inflammatory
properties beyond its insulin-sensitizing effects (8). In addition,
a proaggregatory platelet phenotype has been described in
adiponectin-deficient mice, and recombinant adiponectin in-
hibited enhanced platelet aggregation (10), providing a new
link between adipose tissue and thrombosis. Platelets contrib-
ute critically to the development and progression of cardiovas-
cular diseases, but so far there is no evidence of the presence
of adiponectin receptors on platelets. The present study dem-
onstrates by two different techniques that this cell type ex-
presses these receptors; thus, platelets comprise a target for
new antiatherosclerotic actions of adiponectin. However, very
few studies have evaluated the direct effect of adiponectin on
platelets. A previous report demonstrated that adiponectin has
effects on human and murine platelets (19). The kind of
recombinant adiponectin employed is of relevance, as this
study showed that recombinant globular adiponectin, but not
full-length adiponectin, stimulated platelet aggregation and
dense granule secretion. Another study found that low concen-
trations of adiponectin (0.5 g/ml) did not influence the
effects of ADP and collagen on platelet adhesion (5).
By contrast, our results show that exposure of platelets to
full-length adiponectin at the concentrations that are found in
plasma in lean individuals (10–30 g/ml) inhibited platelet ag-
gregation. Also, adiponectin exists in different multimeric iso-
forms that may have different biological activities, and the high-
molecular-weight oligomers correlate better with metabolic pa-
rameters (6) (16). Future studies will need to clarify the effect of
the different multimeric isoforms on platelet function, but our
findings provide a new link between obesity and cardiovascular
pathologies and suggest that alteration of adiponectin concentra-
tions could alter the human thromboembolic potential.
Effects of adiponectin on sCD40L release. Activated platelets
express CD40L in the surface that is cleaved and released. The
binding of sCD40L to its receptor CD40 participates in the
initiation, progression, and weakening of the atheroma plaques.
Also, the involvement of the CD40-CD40L pathway in athero-
thrombosis has been extensively studied (1), although the exact
mechanisms underlying this association remain under constant
study. We (15) have previously shown that adiponectin down-
regulates the CD40-CD40L dyad in macrophages and endothelial
cells, but so far the effect on platelets has not been investigated.
The novel observation that adiponectin is capable of preventing
platelet sCD40L release demonstrates that this adipokine has a
protector role from platelet activity and provides a new link
between obesity and thrombosis.
Limitations. One limitation of the present study is that in vitro
platelet aggregation studies have been performed in healthy do-
nors, adding adiponectin to the PRP. Therefore the adiponectin is
additional to that already present in the plasma, so these are
relatively high concentrations of adiponectin. Although we did not
find differences in AdipoR1 and AdipoR2 expression in patients
with and without MS, future studies will be required to evaluate
whether platelets from different donors respond differently to
adiponectin. The finding of adiponectin receptors is preliminary,
and more studies should definitively clarify the expression; also,
the possibility that adiponectin exerts its effects on platelets by
binding to other receptor cannot be excluded. Also, to show
specificity of the adiponectin effects, we blocked the adipokine
with an antibody before adding it to the platelets. It is possible that
the antibody does not bind completely to the portion that interacts
Table 2. Correlations of P-selectin, sCD40L, and
adiponectin in the entire population
Variables Correlations
R P
P-selectin
Diastolic blood pressure 0.36 0.048
Triglycerides, (mg/dl) 0.54  0.001
Cholesterol, (mg/dl) 0.33 0.038
sCD40L, (ng/ml) 0.38 0.039
Platelet count (10E9/l) 0.44 0.006
sCD40L
Waist circumference 0.51 0.044
HDL 40/50 0.53 0.023
Triglycerides 0.49 0.006
Platelet count 0.35 0.041
Adiponectin
BMI 0.33 0.050
Triglycerides 0.49 0.001
HDL-cholesterol 0.59 0.001
Glucose 0.46 0.001
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with its receptor, which could explain the reduction in the ob-
served effects, but not the full blockade.
Another limitation is that we employed PRP, not isolated
platelets, for the in vitro experiments. According to our experience
in previous experiments, washed platelets and PRP yield compa-
rable results when one is evaluating aggregation and release of
activation markers. Thus, since obtaining washed platelets is
tedious, and very often they activate in the process of isolation, we
decided to employ PRP.
In summary, this study describes increased sCD40L and plate-
let aggregation associated with low adiponectin in MS and pro-
vides novel evidence demonstrating that adiponectin has anti-
thrombotic properties, since it inhibits platelet aggregation and
activation. These findings suggest that the hypoadiponectinemia
found in patients with MS could in part contribute to the increased
risk of vascular thrombosis as it indirectly affects hemostasis.
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